Intracranial hypertension after MECT: successful transition to rTMS for refractory auditory hallucinations: a case report
Abstract
A 21-year-old female patient with schizophrenia, whose primary symptom was refractory auditory hallucinations, developed intracranial hypertension syndrome following her first session of modified electroconvulsive therapy (MECT), presenting with severe headache, projectile vomiting, diplopia and meningeal signs. She subsequently received 1 Hz repetitive transcranial magnetic stimulation (rTMS) applied to the left temporo-parietal cortex with each session delivering 1,500 pulses at 74% of the resting motor threshold. Her auditory hallucinations diminished markedly 3 days after completing rTMS and resolved completely 1 week later, accompanied by improved social functioning. No recurrence was observed during 3 weeks of follow-up. This case primarily demonstrates that rTMS may represent a safe and effective alternative for patients with refractory auditory hallucinations who are intolerant to MECT. It serves as a clinical reminder to maintain vigilance for elevated intracranial pressure following MECT, particularly in patients with a history of migraine.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.